MDxHealth reported mixed Q2 2026 earnings, missing on EPS but beating revenue expectations, and reaffirmed strong full-year sales guidance above consensus. The company is strategically focusing on its core prostate cancer business and expects to return to positive adjusted EBITDA by the end of 2026, leading to a significant stock surge.
MDxHealth (MDXH) reported a mixed second quarter, with an EPS miss but a revenue beat, which is often overlooked by the market if future prospects are strong. The key catalyst here is the reaffirmed 2026 sales guidance of $110M-$115M, significantly above the $98.814M consensus, coupled with the strategic decision to discontinue the Resolve UTI offering to focus on the higher-margin prostate cancer business. This strategic pivot, along with the expectation of returning to positive adjusted EBITDA by year-end 2026, signals improved financial health and operational efficiency. The market reacted very positively, with the stock surging over 127%, indicating that investors are buying into the company's growth trajectory and profitability outlook. For traders, the short-term opportunity was in the immediate price action, while long-term investors will watch for sustained revenue growth and actual EBITDA realization.